Lupin receives U.S. FDA approval for generic Modafinil Tablets USP 100 mg and 200 mg, bioequivalent to Provigil, for excessive sleepiness.
Written By: Dishali Desai, PharmD
Reviewed By: Pharmacally Editorial Team
Lupin has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) to market Modafinil Tablets USP in 100 mg and 200 mg strengths. The clearance establishes the product as therapeutically and bioequivalent to the reference listed drug (RLD), Provigil® Tablets, marketed by Nuvo Pharmaceuticals (Ireland) DAC. This regulatory clearance authorizes Lupin to commercialize a generic equivalent of the wakefulness-promoting agent across the United States.
Therapeutic Indications and Clinical Role
Modafinil is indicated to improve wakefulness in adult patients who experience excessive daytime sleepiness associated with clinically diagnosed narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). As a wakefulness-promoting agent, the drug provides symptomatic relief by targeting daytime somnolence rather than altering or correcting the underlying pathophysiology of the primary sleep disorder. In conditions like OSA, modafinil serves as an adjunct to primary airway obstruction therapies rather than a replacement.
Market Valuation and Commercial Outlook
The approval represents a strategic expansion of Lupin’s U.S. central nervous system portfolio. According to IQVIA MAT July 2026 sales figures, the U.S. market for the reference product and its bioequivalents generated an estimated $70.7 million in annual sales. By securing clearance for both standard market dosage strengths, Lupin gains full market parity with the RLD. The timing, scale, and competitive positioning of the commercial launch will depend on prevailing market access dynamics, distribution networks, and generic pricing structures.
Reference
Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP – Lupin | Press Release
About the Writer
Dishali Desai (LinkedIn) is a PharmD professional with expertise in clinical pharmacy, evidence-based healthcare writing, and published work on Brugada syndrome and ADR reporting.
Her interests include guideline integration, multimodal therapy, pharmacogenomics, and antibiogram utilization, with a focus on clinical evidence and treatment decisions.
As a healthcare writer, she translates complex clinical information into clear, accurate, and evidence-informed medical content.
